Výsledky vyhledávání - "Thomas A. Marsland"

Results of a Phase II Trial of Gemcitabine in Patients with Non–Small-Cell Lung Cancer and a Performance Status of 2

Autor: Marcus A. Neubauer, Habib M. Ghaddar, Craig H. Reynolds, Marcos G. Joppert, Thomas A. Marsland, Thomas Whittaker, Lina Asmar

Publikováno v: Clinical Lung Cancer. 6:245-249

This trial was designed to determine the 1-year survival rate, efficacy, progression-free survival (PFS), and toxicity with gemcitabine in patients with stage IIIB (with pleural effusion) or stage IV non-small-cell lung cancer (NSCLC) with Eastern Co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7391e45c1932224b20fbceef57a1ce
https://doi.org/10.3816/clc.2005.n.004

Zobrazit plný text záznamu

Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report

Autor: Burt, Zweigenhaft, Linda, Bosserman, James T, Kenney, Grant D, Lawless, Thomas A, Marsland, Craig K, Deligdish, Douglas S, Burgoyne, Kevin B, Knopf, Douglas M, Long, Patrick, McKercher, Gary M, Owens, John E, Hennessy, James R, Lang, Jennifer, Malin, Leonard, Natelson, Matthew C, Palmgren, Jayson, Slotnik, Lillie D, Shockney, F Randy, Vogenberg

Publikováno v: American healthdrug benefits. 6(5)

The AVBCC Annual Meeting experiences exponential growth in attendance and participation as oncologists, payers, employers, managed care executives, patient advocates, and drug manufacturers convened in Hollywood, FL, on May 2-5, 2013, for the Third A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::87e55cb2feeef72ceba0ebe4fdcbc88b
https://pubmed.ncbi.nlm.nih.gov/24991360

Zobrazit plný text záznamu

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

Autor: Martin Sebastian, Rafat Ansari, Claire Beadman, Mansoor N. Saleh, Robert Pirker, Wolfgang Pfeifer, Goetz H. Kloecker, Joan H. Schiller, Michael Thomas, Robert D. McCroskey, Thomas A. Marsland, Philipp Schütt, Joachim von Pawel, Raffael Kurek, Mark A. Socinski

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 5(12)

Introduction This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27237601b9a777060cfd46ced220b1f1
https://pubmed.ncbi.nlm.nih.gov/20978446

Zobrazit plný text záznamu

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

Autor: Suresh S. Ramalingam, Thomas A. Marsland, Elizabeth H. Butler, Richard A. Guidice, Ronald G. Steis, Marshall T. Schreeder, Chandra P. Belani

Publikováno v: Cancer. 113(9)

BACKGROUND. Cetuximab, an immunoglobulin (Ig) G1 chimeric monoclonal antibody against the epidermal growth factor receptor, has demonstrated evidence of activity in nonsmall cell lung cancer (NSCLC). When administered in combination with carboplatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecd280c5bc2611858d23eb55a9d48a7c
https://pubmed.ncbi.nlm.nih.gov/18816622

Zobrazit plný text záznamu

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer

Autor: D.H Garfield, Lina Asmar, Thomas A. Marsland, J.J Nemunaitis, M.A Gregurich, Marcos G. Joppert, P Khandelwal

Publikováno v: Lung cancer (Amsterdam, Netherlands). 39(2)

This trial was designed to determine the 1-year survival rate, efficacy, and safety, produced by topotecan and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (ANSCLC). Fifty-three patients were enrolled; 51 received tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::065f40f62937bd0cdc0c1ef767a505c7
https://pubmed.ncbi.nlm.nih.gov/12581576

Zobrazit plný text záznamu

Rituximab Induces High Response Rate and Prolonged Remission in Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Retrospective Analysis

Autor: Linda S. Sylvester, Thomas A. Marsland, Morris S. Dees, Salahattin M. Sanal, Shalin Shah, Joseph W. Sullivan, Troy H. Guthrie, Melissa J. Hanson

Publikováno v: Blood. 104:3956-3956

Background: Rituximab is a chimeric monoclonal antibody targeting CD 20+ B lymphocytes (Rastetter et al, 2004). Combination of rituximab with conventional chemotherapeutic agents has become the mainstay of treatment for B-cell Non-Hodgkin’s Lymphom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb387037c7659b88e1e57c1ee18be3ad
https://doi.org/10.1182/blood.v104.11.3956.3956

Zobrazit plný text záznamu

Estrogen receptor status and response to chemotherapy in advanced breast cancer: The tufts-shattuck-pondville experience

Autor: Thomas A. Marsland, Charles Rosenbaum, Leo L. Stolbach, Shanthi Raam, Joseph L. Cohen

Publikováno v: Cancer. 46:2919-2921

88 patients with advanced breast cancer were retrospectively reviewed to compare (ER) estrogen receptor data with response to cytotoxic chemotherapy. All assays were done in a single laboratory and all patients were cared for at a single institution.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81db6b31fbc0d13dfe676f181cae2987
https://doi.org/10.1002/1097-0142(19801215)46:12+<2919::aid-cncr2820461434>3.0.co

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání